ImmunoGen Regroups After FORWARD Setback, Looks To New Ovarian Cancer Phase III

 
• By Bridget Silverman

US FDA dashes hopes for accelerated approval of mirvetuximab soravtansine based on subgroup data, but will work with ImmunoGen to design a new trial focused on highly FRα-positive patients.

The hands of the captain and a steering wheel boat port services

More from Approval Standards

More from Pathways & Standards